Led · Equity · Jun 2026

Rejuvenate Bio develops gene therapies aimed at extending healthy lifespan and treating chronic, age-associated diseases by combining advances in gene delivery, translational biology, and longevity science. The company has built a pipeline targeting clinically validated gene targets with a delivery approach designed for well-tolerated, durable expression. Rejuvenate Bio is developing therapies for companion animals with the stated goal of translating insights toward human health applications. The company was founded on research from the Wyss Institute at Harvard Medical School and is headquartered in San Diego, CA. Following the announced $6 million financing, Rejuvenate Bio has also entered a strategic R&D collaboration with Merck Animal Health to advance a targeted animal-health gene therapy program.

Participated · Series A · Jun 2024

Raydiant Oximetry is a venture-backed, clinical-stage medical device company based in San Ramon, California, focused on improving outcomes for mothers and babies during childbirth. The company was founded by Neil P. Ray, MD, and has developed Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a vacuum-induced surgical tool for OB/GYN applications. Raydiant’s core product work centers on fetal pulse oximetry to better identify fetal distress and potentially avoid medically unnecessary C-sections. The company plans to use prize funding and development sprints to further advance and de-risk its technologies for clinical adoption. Raydiant frames its innovations as transformative for monitoring practices during labor and delivery and is advancing through clinical-stage development and expert evaluation. Raydiant Oximetry, based in San Ramon, CA and founded by Neil P. Ray, develops two clinical-stage technologies: Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a surgical device to quantify blood loss, treat uterine atony and prevent postpartum hemorrhage after C-section. The company is focused on improving outcomes for mothers and babies during childbirth. Raydiant plans to use its new funding to support two clinical studies of Lumerah and Daisy being conducted at Eastern Virginia Medical School under Dr. George Saade. The studies aim to generate clinical evidence to validate performance and safety in labor and delivery settings. Raydiant is pursuing regulatory and clinical pathways typical for medical devices as it advances these technologies through clinical evaluation. The company recently raised extension funding to advance those clinical programs. Raydiant Oximetry is a clinical-stage medical device company based in San Ramon, CA focused on improving women’s and neonatal health. Its core product is LUMERAH™, a non-invasive fetal oximeter designed to detect fetal distress during labor and delivery. LUMERAH is an investigational medical device and is not currently approved for commercial sale. The company is led by founder and CEO Neil Ray, MD. Raydiant raised $5M in a Series A2 financing and intends to use the funds to complete a clinical study at the University of Texas Medical Branch in Galveston. The UTMB study, with Dr. George Saade as principal investigator, is part of clinical research supported by the NIH Maternal‑Fetal‑Medicine Network to advance validation of the device. Raydiant Oximetry is a Mountain View, California medical device company that has developed a noninvasive fetal monitor to directly measure a baby’s oxygenation during pregnancy and childbirth. Founded in 2016 and led by CEO Dr. Neil P. Ray, the company is in residence at the Fogarty Institute for Innovation. It has demonstrated feasibility of the technology in pregnant women through an IRB‑approved study and validated results in animal models. Raydiant holds two issued patents protecting the core technology and expects up to ten more patents over the next 36 months. The company raised $1M in seed funding and intends to use the proceeds to build a subsequent prototype with improved accuracy and reliability.

Participated · Series B · Apr 2023

SentiAR develops augmented reality visualization technology for medical procedures, centered on its CommandEP product that creates real-time 3D holographic views of patient anatomy. CommandEP integrates existing imaging systems and uses a headset to provide hands-free manipulation of patient data and live catheter locations during cardiac ablation. The system gives physicians a 360-degree interactive view of heart anatomy and has been shown to improve navigation accuracy in the heart by up to 50%. The company says the new funding will support additional partnerships and wider clinical deployments of CommandEP. SentiAR is based in St. Louis, Missouri, and positions its technology as a workflow-friendly AR tool designed not to impede clinical procedures. The company highlights clinical and strategic collaborations as central to its commercialization plans. SentiAR develops a mixed-reality visualization platform for use during interventional procedures, beginning with cardiac ablation and treatment of atrial fibrillation. Its FDA 510(k) cleared CommandEP system receives imaging data from electroanatomic mapping systems and creates a 3D holographic image via proprietary data-flow and visualization algorithms. The patented system displays real-time catheter positions in the patient’s heart through a wearable headset and relies on a custom AR engine for performance. SentiAR’s technology was spun out of Washington University in St. Louis by Dr. Jennifer Silva and Dr. Jonathan Silva. Led by CEO Berk Tas, the company plans to use new funding to accelerate innovation on the CommandEP system.

Led · Series B · Aug 2022

Avenda Health, based in Culver City, CA and led by CEO Shyam Natarajan, develops AI-enabled tools for prostate cancer care. Its core product, iQuest, is a deep-learning patient management software that maps a patient’s cancer in 3D and uncovers disease hidden within traditional MRI mapping. The FocalPoint System, powered by iQuest, provides an in-office ultrasound-guided soft tissue ablation option intended to preserve quality of life by sparing healthy tissue. FocalPoint is FDA cleared for soft tissue ablation, while iQuest and its use with FocalPoint are for investigational use only and not FDA cleared. The company says its software gives physicians precise, patient-specific information to support treatment decisions. Avenda plans to use new funding to accelerate adoption of iQuest and to continue clinical evidence development. Avenda Health is a biomedical device company based in Santa Monica that has developed a fiber-optic laser device to treat prostate tumors. The device is designed to ablate prostate tumors without compromising urinary or sexual function. The company was launched in June 2017 and was founded by Shyam Natarajan (CEO), Brittany Berry-Pusey (COO), and Dr. Leonard S. Marks (CMO). Avenda closed a funding round in which it sold $3,325,000 in securities to 18 investors, according to an SEC filing released April 11. The article does not report revenue, user metrics, prior financings, or commercialization status. Leadership includes Natarajan, an adjunct UCLA bioengineering professor who previously served as program manager of the UCLA Business of Science Center.

Participated · Series B · Aug 2022

ATLAS Space Operations offers Ground Station as a Service (GaaS) and Ground Software as a Service (GSaaS) through its proprietary Freedom® software, enabling unified access to a federated network of antennas. The company operates over 50 antennas across more than 34 ground stations and supports LEO, MEO, and GEO orbits for commercial, civil, and defense customers. Freedom® software centralizes antenna networks, automates communications, enables dynamic scheduling, and provides near real-time troubleshooting and rapid onboarding. ATLAS reports a 100% contract renewal rate, underscoring heavy customer reliance on its ground infrastructure. Founded in 2015, the company moved its headquarters to Traverse City, Michigan in 2017 and maintains an office in Colorado Springs, Colorado. Management cites plans to use new capital to meet rising industry demand and to execute U.S. and EMEA expansion strategies. ATLAS Space Operations provides Ground Software as a Service (G-SaaS) through its Freedom™ software platform and a global antenna network to integrate disparate ground station networks for government and commercial clients. The company positions its Freedom™ solution as an industry-disruptive software layer that federates networks and maximizes ground-station value. ATLAS plans to accelerate international growth and expand its team to deliver enterprise-level G-SaaS for commercial customers and the DoD Hybrid Space Architecture. The company intends to increase market share in the private sector while supporting government requirements. ATLAS has been recognized by the World Teleport Association as one of the top three fastest-growing teleport operators worldwide for the past two years and was named the 15th fastest-growing software company in 2020 by Inc. 5000. Its mission statement is to connect humanity through space by combining software and a global antenna network.